ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Verma on Advancements in Treatment of HER2-Positive Breast Cancer

Sunil Verma, MD
Published: Saturday, Mar 12, 2016



Sunil Verma, MD, department head, Clinical Department of Oncology, Calgary Zone, medical director, Tom Baker Cancer Centre, discusses recent advancements in the field of HER2-positive breast cancer.

One of the key advancements in the field is the understanding that treatment of HER2-positive breast cancer requires ongoing suppression of the HER2 receptor; therefore, an antibody or a tyrosine kinase inhibitor is necessary in the treatment paradigm, Verma explains. Secondly, pertuzumab in the first-line setting has been an important advance, as it demonstrates improvements in progression-free and overall survival. Additionally, T-DM1 can be used in the second-line setting and beyond to show these same benefits.

The median survival for patients with HER2-positive breast cancer exceeds 5 years, Verma says. However, critical issues that still remain include targeting patients with brain metastases and determining duration of therapies.

<<< View more from the 33rd Annual Miami Breast Cancer Conference



Sunil Verma, MD, department head, Clinical Department of Oncology, Calgary Zone, medical director, Tom Baker Cancer Centre, discusses recent advancements in the field of HER2-positive breast cancer.

One of the key advancements in the field is the understanding that treatment of HER2-positive breast cancer requires ongoing suppression of the HER2 receptor; therefore, an antibody or a tyrosine kinase inhibitor is necessary in the treatment paradigm, Verma explains. Secondly, pertuzumab in the first-line setting has been an important advance, as it demonstrates improvements in progression-free and overall survival. Additionally, T-DM1 can be used in the second-line setting and beyond to show these same benefits.

The median survival for patients with HER2-positive breast cancer exceeds 5 years, Verma says. However, critical issues that still remain include targeting patients with brain metastases and determining duration of therapies.

<<< View more from the 33rd Annual Miami Breast Cancer Conference


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x